Payment overview · 2025
General Payments
$21,636.50
118 reported records · 22 companies
Healthcare provider profile · identity verified
John J Doolan, DPM
Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · NEW YORK, NY · NPI 1073540480
Verified facts
What the public records show
CMS Open Payments records show John J Doolan, DPM received $21,636.50 in general payments during 2025 across 118 reported records.
PolyNovo North America LLC accounted for 42.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PolyNovo North America LLC | Unresolved — no canonical attribution shown | $9,108.33 | 42.1% | 44 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $7,281.97 | 33.7% | 22 | 2025 |
| Trilliant Surgical LLC. | Unresolved — no canonical attribution shown | $1,474.20 | 6.8% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $1,164.21 | 5.4% | 9 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $345.40 | 1.6% | 3 | 2025 |
| Gramercy Extremity Orthopedics LLC | Unresolved — no canonical attribution shown | $286.46 | 1.3% | 1 | 2025 |
| Orthofix Medical, Inc. | Unresolved — no canonical attribution shown | $257.87 | 1.2% | 4 | 2025 |
| Linvatec Corporation | Unresolved — no canonical attribution shown | $255.46 | 1.2% | 2 | 2025 |
| Next Science LLC | Unresolved — no canonical attribution shown | $250.59 | 1.2% | 3 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $213.20 | 1.0% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$185.25 | 0.9% | 2 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $181.11 | 0.8% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $165.73 | 0.8% | 9 | 2025 |
| MedShape, Inc. | Unresolved — no canonical attribution shown | $136.14 | 0.6% | 1 | 2025 |
| Arteriocyte Medical Systems, Inc. | Unresolved — no canonical attribution shown | $110.47 | 0.5% | 1 | 2025 |
| Access Pro Medical, LLC | Unresolved — no canonical attribution shown | $72.90 | 0.3% | 2 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $31.92 | 0.1% | 1 | 2025 |
| Avita Medical Americas, LLC | Unresolved — no canonical attribution shown | $31.24 | 0.1% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $23.65 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.19 | 0.1% | 1 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $20.33 | 0.1% | 1 | 2025 |
| Dynasplint Systems Inc. | Unresolved — no canonical attribution shown | $16.88 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,844.43 | 104 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,000.00 | 4 |
| Consulting Fee | $6,000.00 | 2 |
| Travel and Lodging | $2,505.61 | 7 |
| Royalty or License | $286.46 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NOVOSORB BTM Normalized: novosorb btm |
Device | PolyNovo North America LLC | $9,108.33 | 44 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $4,153.10 | 9 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $3,149.50 | 7 | 2025 |
Source payment records
|
|||||
| Arsenal Ankle Normalized: arsenal ankle |
Device | Trilliant Surgical LLC. | $1,329.53 | 1 | 2025 |
Source payment records
|
|||||
| PROSTEP MICA Normalized: prostep mica |
Device | Stryker Corporation | $492.54 | 3 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $345.40 | 3 | 2025 |
Source payment records
|
|||||
| VARIAX Normalized: variax |
Device | Stryker Corporation | $339.67 | 2 | 2025 |
Source payment records
|
|||||
| HOFFMANN Normalized: hoffmann |
Device | Stryker Corporation | $337.88 | 2 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $298.12 | 3 | 2025 |
Source payment records
|
|||||
| NUSHIELD Normalized: nushield |
Medical Supply | Organogenesis Inc. | $260.41 | 2 | 2025 |
Source payment records
|
|||||
| Physio-Stim Normalized: physio stim |
Device | Orthofix Medical, Inc. | $257.87 | 4 | 2025 |
Source payment records
|
|||||
| BIOBRACE 23MM Normalized: biobrace 23mm |
Device | Linvatec Corporation | $255.46 | 2 | 2025 |
Source payment records
|
|||||
| BlastX Normalized: blastx |
Device | Next Science LLC | $250.59 | 3 | 2025 |
Source payment records
|
|||||
| Xperience Normalized: xperience |
Device | Next Science LLC | $250.59 | 3 | 2025 |
Source payment records
|
|||||
| NOVACHOR Normalized: novachor |
Medical Supply | Organogenesis Inc. | $240.00 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $185.25 | 2 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $181.11 | 2 | 2025 |
Source payment records
|
|||||
| BIOSKIN Normalized: bioskin |
Device | Stryker Corporation | $172.41 | 1 | 2025 |
Source payment records
|
|||||
| GRAVITY Normalized: gravity |
Device | Stryker Corporation | $172.41 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 3DI Normalized: ortholoc 3di |
Device | Stryker Corporation | $172.41 | 1 | 2025 |
Source payment records
|
|||||
| 7 X 23MM CITRELOCK IMPLANT Normalized: 7 x 23mm citrelock implant |
Device | Stryker Corporation | $167.34 | 1 | 2025 |
Source payment records
|
|||||
| CITREFIX Normalized: citrefix |
Device | Stryker Corporation | $167.34 | 1 | 2025 |
Source payment records
|
|||||
| PANGEA Normalized: pangea |
Device | Stryker Corporation | $167.34 | 1 | 2025 |
Source payment records
|
|||||
| SONICANCHOR Normalized: sonicanchor |
Device | Stryker Corporation | $167.34 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $165.73 | 9 | 2025 |
Source payment records
|
|||||
| AUGMENT INJECTABLE Normalized: augment injectable |
Device | Stryker Corporation | $156.14 | 2 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $150.84 | 3 | 2025 |
Source payment records
|
|||||
| Arsenal Sinus Support Plate Normalized: arsenal sinus support plate |
Device | Trilliant Surgical LLC. | $144.67 | 1 | 2025 |
Source payment records
|
|||||
| DynaNail Normalized: dynanail |
Device | MedShape, Inc. | $136.14 | 1 | 2025 |
Source payment records
|
|||||
| HERCULES SUTURE ANCHOR SYSTEM Normalized: hercules suture anchor system |
Device | Linvatec Corporation | $111.14 | 1 | 2025 |
Source payment records
|
|||||
| Magellan Normalized: magellan |
Device | Arteriocyte Medical Systems, Inc. | $110.47 | 1 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $97.35 | 3 | 2025 |
Source payment records
|
|||||
| MATRIDERM Normalized: matriderm |
Device | Access Pro Medical, LLC | $72.90 | 2 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $62.36 | 2 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $43.49 | 1 | 2025 |
Source payment records
|
|||||
| Cohealyx Normalized: cohealyx |
Device | Avita Medical Americas, LLC | $31.24 | 1 | 2025 |
Source payment records
|
|||||
| Permeaderm Normalized: permeaderm |
Device | Avita Medical Americas, LLC | $31.24 | 1 | 2025 |
Source payment records
|
|||||
| Recell Normalized: recell |
Device | Avita Medical Americas, LLC | $31.24 | 1 | 2025 |
Source payment records
|
|||||
| 3M Coban Normalized: 3m coban |
Device | Solventum Corporation | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| KerraMax Care Normalized: kerramax care |
Device | Solventum Corporation | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Dynasplint Normalized: dynasplint |
Device | Dynasplint Systems Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| ORTHOLOC 2 LAPIFUSE Normalized: ortholoc 2 lapifuse |
Device | Stryker Corporation | $10.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Terbinafine Hcl | Terbinafine Hcl | 60 | 31 |
| Ketoconazole | Ketoconazole | 37 | 18 |
| Santyl | Collagenase Clostridium Hist. | 24 | 13 |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,636.50 · 118 records | PolyNovo North America LLC | 3M Coban, 7 X 23MM CITRELOCK IMPLANT, ACTIV.A.C., AFFINITY, APLIGRAF, AUGMENT INJECTABLE, Altius, Arsenal Ankle, Arsenal Sinus Support Plate, BIOBRACE 23MM, BIOSKIN, BlastX, CITREFIX, COLLAGENASE SANTYL, CYGNUS DUAL, Cohealyx, DynaNail, Dynasplint, EXOGEN ULTRASOUND BONE HEALING SYSTEM, GRAVITY, HERCULES SUTURE ANCHOR SYSTEM, HOFFMANN, INCEPTIV, KerraMax Care, LAPIPLASTY SYSTEM 1, MATRIDERM, Magellan, NOVACHOR, NOVOSORB BTM, NUSHIELD, ORTHOLOC 2 LAPIFUSE, ORTHOLOC 3DI, PANGEA, PROMOGRAN PRISMA, PROSTEP MICA, PURAPLY WOUND MATRIX, Permeaderm, Physio-Stim, Recell, Restrata Wound Matrix, SONICANCHOR, TEFLARO, TMC NANOPLASTY SYSTEM, VARIAX, VIA MATRIX, Xperience | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error